125 related articles for article (PubMed ID: 10134128)
1. A vancomycin drug use evaluation and economic analysis in a cancer treatment centre.
Dranitsaris G; Pilla NJ; McGreer A
Can J Hosp Pharm; 1994 Apr; 47(2):59-64. PubMed ID: 10134128
[TBL] [Abstract][Full Text] [Related]
2. A pharmacoeconomic model to evaluate antibiotic costs.
Garrelts JC; Horst WD; Silkey B; Gagnon S
Pharmacotherapy; 1994; 14(4):438-45. PubMed ID: 7937280
[TBL] [Abstract][Full Text] [Related]
3. Impact of a target drug monitoring program on the usage of clindamycin.
Gin AS; Lipinski LA; Honcharik N
Can J Hosp Pharm; 1994 Apr; 47(2):53-8. PubMed ID: 10134127
[TBL] [Abstract][Full Text] [Related]
4. Developing and implementing guidelines to promote appropriate use of fluconazole therapy in an AIDS clinic.
Anassi EO; Egbunike IG; Akpaffiong MJ; Ike EN; Cate TR
Hosp Pharm; 1994 Jun; 29(6):576-8, 581-2, 585-6. PubMed ID: 10134178
[TBL] [Abstract][Full Text] [Related]
5. Ciprofloxacin use under a reserved drug and stepdown promotion program.
Frighetto L; Martinusen SM; Mamdani F; Jewesson PJ
Can J Hosp Pharm; 1995 Feb; 48(1):35-42. PubMed ID: 10141061
[TBL] [Abstract][Full Text] [Related]
6. A clinical decision process model for evaluating vancomycin use with modified HICPAC guidelines. Hospital Infection Control Practice Advisory Committee.
Salemi C; Becker L; Morrissey R; Warmington J
Clin Perform Qual Health Care; 1998; 6(1):12-6. PubMed ID: 10177043
[TBL] [Abstract][Full Text] [Related]
7. Reducing outpatient costs of nonsteroidal antiinflammatory drugs at a Department of Veterans Affairs teaching hospital.
Drexler PG; Lambdin CS
J Pharm Technol; 1993; 9(1):10-3. PubMed ID: 10123760
[TBL] [Abstract][Full Text] [Related]
8. Vancomycin use in 2 Ontario tertiary care hospitals: a survey.
Kwan T; Lin F; Ngai B; Loeb M
Clin Invest Med; 1999 Dec; 22(6):256-64. PubMed ID: 10664867
[TBL] [Abstract][Full Text] [Related]
9. Current treatment of gram-positive infections: focus on efficacy, safety, and cost minimalization analysis of teicoplanin.
Crane VS; Garabedian-Ruffalo SM
Hosp Formul; 1992 Dec; 27(12):1199-200, 1203-4, 1207-10. PubMed ID: 10122506
[TBL] [Abstract][Full Text] [Related]
10. A targeted review of vancomycin use.
Piquette RK
Can J Hosp Pharm; 1991 Apr; 44(2):83-7. PubMed ID: 10111726
[TBL] [Abstract][Full Text] [Related]
11. Drug utilization & therapeutic intervention programs: pharmacy services that pay for themselves.
Condron JH; Mann JL
Can J Hosp Pharm; 1994 Oct; 47(5):203-8. PubMed ID: 10137698
[TBL] [Abstract][Full Text] [Related]
12. Impact of linezolid on economic outcomes and determinants of cost in a clinical trial evaluating patients with MRSA complicated skin and soft-tissue infections.
McKinnon PS; Sorensen SV; Liu LZ; Itani KM
Ann Pharmacother; 2006 Jun; 40(6):1017-23. PubMed ID: 16720705
[TBL] [Abstract][Full Text] [Related]
13. The economic impact of clinical pharmacists' unsolicited recommendations.
Torok N; Brown G
Hosp Pharm; 1992 Dec; 27(12):1052-3, 1056-8, 1060. PubMed ID: 10122507
[TBL] [Abstract][Full Text] [Related]
14. Health economics assessment study of teicoplanin versus vancomycin in Gram-positive infections.
Portolés A; Palau E; Puerro M; Vargas E; Picazo JJ
Rev Esp Quimioter; 2006 Mar; 19(1):65-75. PubMed ID: 16688294
[TBL] [Abstract][Full Text] [Related]
15. Managing high cost and biotech drugs: two institutions' perspectives.
Dana WJ; McWhinney B
Hosp Formul; 1994 Sep; 29(9):638-45. PubMed ID: 10137060
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of telavancin versus vancomycin for treatment of complicated skin and skin structure infections.
Laohavaleeson S; Barriere SL; Nicolau DP; Kuti JL
Pharmacotherapy; 2008 Dec; 28(12):1471-82. PubMed ID: 19025428
[TBL] [Abstract][Full Text] [Related]
17. Hospital drug therapy cost containment through a preferred medicines list and drug utilisation review system.
Pearce MJ; Begg EJ
N Z Med J; 1994 Mar; 107(974):101-4. PubMed ID: 8127505
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of ondansetron prescribing in US academic medical centers.
Vermeulen LC; Matuszewski KA; Ratko TA; Butler CD; Burnett DA; Vlasses PH
Arch Intern Med; 1994 Aug; 154(15):1733-40. PubMed ID: 8042890
[TBL] [Abstract][Full Text] [Related]
19. How a CQI program improved aminoglycoside use in a community hospital.
Wade WE; McCall CY
Hosp Formul; 1995 Feb; 30(2):114-6. PubMed ID: 10140350
[TBL] [Abstract][Full Text] [Related]
20. Effect of antibiotic order form guiding rational use of expensive drugs on cost containment.
Sirinavin S; Suvanakoot P; Sathapatayavongs B; Malatham K
Southeast Asian J Trop Med Public Health; 1998 Sep; 29(3):636-42. PubMed ID: 10437971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
